The authors are grateful to Fundação para a Ciência e a Tecnologia (FCT, Portugal), COMPETE/QREN/EU for financial support to this work (bilateral cooperation action Portugal/Serbia 2011), to CIMO (strategic project PEst-OE/AGR/UI0690/2011), and to Serbian Ministry of Education and Science for financial support (grant number 173032). L. Barros also thanks FCT, POPH-QREN and FSE for her grant (SFRH/BPD/4609/2008).
The genus Penicillium is well known for its importance in drug and food production. Certain species are produced on an industrial scale for the production of antibiotics (e.g. penicillin) or for insertion in food (e.g. cheese). In the present work, three Penicillium species, part of the natural mycobiota growing on various food products were selected– P. ochrochloron, P. funiculosum and P. verrucosum var. cyclopium. The objective of our study was to value these species from the point of view of production of bioactive metabolites. The species were obtained after inoculation and growth in Czapek and Malt media. Both mycelia and culture media were analyzed to monitor the production of different metabolites by each fungus and their release to the culture medium. The concentrations of sugars, organic acids, phenolic acids and tocopherols, were determined. Antioxidant activity of the phenolic extracts was evaluated, as also the antimicrobial activity of phenolic acids, organic acids and tocopherols extracts. Rhamnose, xylose, fructose and trehalose were found in all the mycelia and culture media; the prevailing organic acids were oxalic and fumaric acids, and protocatechuic and p-hydroxybenzoic acids were the most common phenolic acids; γ-tocopherol was the most abundant vitamin E isoform. Generally, the phenolic extracts corresponding to the mycelia samples revealed higher antioxidant activity. Concerning the antimicrobial activity there were some fluctuations, however all the studied species revealed activity against the tested strains. Therefore, the in vitro bioprocesses can be an alternative for the production of bioactive metabolites that can be used by pharmaceutical industry.
